在线视频色亚洲,欧美中文国产,日本少妇精品不卡

Daiichi Sankyo Full Year 2025 Financial Report Financial statements Daiichi Sankyo's FY2025 Q3 report highlights $4.4 billion in sales for Enhertu (DS-8201) and significant growth in its ADC portfolio. With groundbreaking treatments and strong pipeline advancements, the company is reshaping the oncology landscape.
ASCO 2025: Opening a New Era of "Cancer Eradication" ASCO Discover the latest breakthroughs from ASCO 2025, including innovative cancer treatments, immunotherapy advances, bispecific antibodies, and promising breast cancer therapies shaping the future of oncology.
Carbogen Invests $31M to Expand ADC Linker Production in Switzerland Carbogen AMCIS Swiss CDMO Carbogen AMCIS, in partnership with a Japanese firm, is investing $31 million to expand its ADC linker production capabilities at two Swiss sites, with completion expected by 2027.
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Filing After Trial Misses Survival Goal Biotech Merck and Daiichi Sankyo have withdrawn their FDA application for patritumab deruxtecan after a Phase III trial failed to show significant overall survival benefits in EGFR-mutated NSCLC patients, citing regulatory discussions.
2024 FDA Issued CRLs FDA The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
Enhertu Sales Report 2024 Financial statements Daiichi Sankyo's Enhertu achieved $3.4B in 2024 sales, a 52% YoY increase. The company also reports strong growth in HER2-positive breast cancer treatment and expanded indications in China and the U.S.

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水